EA202193281A1 - Новые соединения и их фармацевтические композиции для лечения заболеваний - Google Patents
Новые соединения и их фармацевтические композиции для лечения заболеванийInfo
- Publication number
- EA202193281A1 EA202193281A1 EA202193281A EA202193281A EA202193281A1 EA 202193281 A1 EA202193281 A1 EA 202193281A1 EA 202193281 A EA202193281 A EA 202193281A EA 202193281 A EA202193281 A EA 202193281A EA 202193281 A1 EA202193281 A1 EA 202193281A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diseases
- treatment
- compounds
- pharmaceutical compositions
- new compounds
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 9
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 230000001771 impaired effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000010072 bone remodeling Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000030172 endocrine system disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1907616.5A GB201907616D0 (en) | 2019-05-29 | 2019-05-29 | Novel compounds and pharmaceutical compositons thereof for the treatment of diseases |
| PCT/EP2020/064368 WO2020239658A1 (en) | 2019-05-29 | 2020-05-25 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202193281A1 true EA202193281A1 (ru) | 2022-03-01 |
Family
ID=67385363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202193281A EA202193281A1 (ru) | 2019-05-29 | 2020-05-25 | Новые соединения и их фармацевтические композиции для лечения заболеваний |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12391679B2 (enExample) |
| EP (1) | EP3976189B1 (enExample) |
| JP (1) | JP7550174B2 (enExample) |
| KR (1) | KR20220015450A (enExample) |
| CN (1) | CN113924146B (enExample) |
| AR (1) | AR119028A1 (enExample) |
| AU (1) | AU2020281650B2 (enExample) |
| BR (1) | BR112021023900A2 (enExample) |
| CA (1) | CA3141683A1 (enExample) |
| CL (1) | CL2021003133A1 (enExample) |
| CO (1) | CO2021017656A2 (enExample) |
| CR (1) | CR20210586A (enExample) |
| DO (1) | DOP2021000227A (enExample) |
| EA (1) | EA202193281A1 (enExample) |
| ES (1) | ES2985528T3 (enExample) |
| GB (1) | GB201907616D0 (enExample) |
| IL (1) | IL288375B1 (enExample) |
| MA (1) | MA56019A (enExample) |
| MX (1) | MX2021013803A (enExample) |
| PE (1) | PE20220503A1 (enExample) |
| PH (1) | PH12021552691A1 (enExample) |
| PL (1) | PL3976189T3 (enExample) |
| SG (1) | SG11202112652RA (enExample) |
| TW (1) | TW202110839A (enExample) |
| WO (1) | WO2020239658A1 (enExample) |
| ZA (1) | ZA202110597B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241435B2 (en) | 2016-09-16 | 2022-02-08 | The General Hospital Corporation | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis |
| WO2020182384A1 (en) | 2019-03-11 | 2020-09-17 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor |
| GB201907558D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| CA3190172A1 (en) * | 2020-08-05 | 2022-02-10 | The General Hospital Corporation | Salt inducible kinase inhibitors |
| USD982434S1 (en) * | 2021-08-31 | 2023-04-04 | Level Up Dice LLC | Dice storage container |
| WO2023066204A1 (zh) * | 2021-10-18 | 2023-04-27 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
| AR128279A1 (es) * | 2022-01-19 | 2024-04-10 | Hoffmann La Roche | Nuevos derivados de bencimidazol piridina |
| CN115304605B (zh) * | 2022-01-21 | 2023-10-03 | 陕西国际商贸学院 | 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用 |
| WO2024003209A1 (en) * | 2022-07-01 | 2024-01-04 | F. Hoffmann-La Roche Ag | Imidazo[4,5-c]pyridine derivatives as sik modulators for the treatment of rheumatoid arthritis |
| US20240124450A1 (en) * | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| CN120239700A (zh) * | 2022-11-17 | 2025-07-01 | 英矽智能科技知识产权有限公司 | 盐诱导激酶(sik)抑制剂及其使用方法 |
| WO2024242169A1 (ja) * | 2023-05-24 | 2024-11-28 | 田辺三菱製薬株式会社 | 塩誘導性キナーゼ阻害化合物及びそれを含む医薬組成物 |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
| TW202517630A (zh) * | 2023-07-19 | 2025-05-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎苯并咪唑吡啶衍生物 |
| WO2025068090A1 (en) * | 2023-09-26 | 2025-04-03 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of diseases |
| WO2025232877A1 (en) * | 2024-05-10 | 2025-11-13 | Insilico Medicine Ip Limited | Salt-inducible kinases (sik) inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534206A (ja) * | 2007-07-20 | 2010-11-04 | メルク・シャープ・エンド・ドーム・コーポレイション | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| WO2012068406A2 (en) * | 2010-11-18 | 2012-05-24 | Ligand Pharmaceuticals Incorporated | Use of hematopoietic growth factor mimetics |
| JP6171149B2 (ja) * | 2010-12-01 | 2017-08-02 | プレイザン カーボン コンポジティーズ，インコーポレイテッド | 複合材物品を形成する方法及びシステム |
| WO2013135612A1 (en) | 2012-03-14 | 2013-09-19 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| CA2997556C (en) * | 2015-09-03 | 2020-12-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1a and uses thereof |
| CN106496222A (zh) * | 2016-09-07 | 2017-03-15 | 华东师范大学 | 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用 |
| ES2908283T3 (es) * | 2017-12-02 | 2022-04-28 | Galapagos Nv | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades |
| CN108358894B (zh) * | 2018-04-26 | 2021-05-07 | 四川大学 | 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用 |
| CA3103304A1 (en) * | 2018-06-15 | 2019-12-19 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| CN118684661A (zh) | 2023-03-21 | 2024-09-24 | 上海美悦生物科技发展有限公司 | 杂芳基类化合物及其药物组合物、制备方法和用途 |
-
2019
- 2019-05-29 GB GBGB1907616.5A patent/GB201907616D0/en not_active Ceased
-
2020
- 2020-05-25 EA EA202193281A patent/EA202193281A1/ru unknown
- 2020-05-25 AU AU2020281650A patent/AU2020281650B2/en active Active
- 2020-05-25 IL IL288375A patent/IL288375B1/en unknown
- 2020-05-25 PH PH1/2021/552691A patent/PH12021552691A1/en unknown
- 2020-05-25 ES ES20728465T patent/ES2985528T3/es active Active
- 2020-05-25 SG SG11202112652RA patent/SG11202112652RA/en unknown
- 2020-05-25 WO PCT/EP2020/064368 patent/WO2020239658A1/en not_active Ceased
- 2020-05-25 MA MA056019A patent/MA56019A/fr unknown
- 2020-05-25 BR BR112021023900A patent/BR112021023900A2/pt unknown
- 2020-05-25 US US17/614,854 patent/US12391679B2/en active Active
- 2020-05-25 KR KR1020217042863A patent/KR20220015450A/ko active Pending
- 2020-05-25 MX MX2021013803A patent/MX2021013803A/es unknown
- 2020-05-25 JP JP2021570425A patent/JP7550174B2/ja active Active
- 2020-05-25 CN CN202080039185.0A patent/CN113924146B/zh active Active
- 2020-05-25 CR CR20210586A patent/CR20210586A/es unknown
- 2020-05-25 PE PE2021001955A patent/PE20220503A1/es unknown
- 2020-05-25 CA CA3141683A patent/CA3141683A1/en active Pending
- 2020-05-25 EP EP20728465.4A patent/EP3976189B1/en active Active
- 2020-05-25 PL PL20728465.4T patent/PL3976189T3/pl unknown
- 2020-05-28 AR ARP200101505A patent/AR119028A1/es not_active Application Discontinuation
- 2020-05-28 TW TW109117844A patent/TW202110839A/zh unknown
-
2021
- 2021-11-03 DO DO2021000227A patent/DOP2021000227A/es unknown
- 2021-11-24 CL CL2021003133A patent/CL2021003133A1/es unknown
- 2021-12-17 ZA ZA2021/10597A patent/ZA202110597B/en unknown
- 2021-12-22 CO CONC2021/0017656A patent/CO2021017656A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020239658A1 (en) | 2020-12-03 |
| EP3976189B1 (en) | 2024-07-03 |
| KR20220015450A (ko) | 2022-02-08 |
| DOP2021000227A (es) | 2022-05-15 |
| MA56019A (fr) | 2022-04-06 |
| AU2020281650B2 (en) | 2025-08-28 |
| IL288375A (en) | 2022-01-01 |
| EP3976189C0 (en) | 2024-07-03 |
| IL288375B1 (en) | 2025-09-01 |
| AR119028A1 (es) | 2021-11-17 |
| JP2022534578A (ja) | 2022-08-02 |
| GB201907616D0 (en) | 2019-07-10 |
| CL2021003133A1 (es) | 2022-07-22 |
| CN113924146A (zh) | 2022-01-11 |
| ZA202110597B (en) | 2024-10-30 |
| MX2021013803A (es) | 2021-12-14 |
| PH12021552691A1 (en) | 2022-03-14 |
| EP3976189A1 (en) | 2022-04-06 |
| TW202110839A (zh) | 2021-03-16 |
| BR112021023900A2 (pt) | 2022-01-18 |
| AU2020281650A1 (en) | 2022-02-03 |
| CO2021017656A2 (es) | 2022-01-17 |
| CN113924146B (zh) | 2024-12-10 |
| CA3141683A1 (en) | 2020-12-03 |
| PE20220503A1 (es) | 2022-04-07 |
| SG11202112652RA (en) | 2021-12-30 |
| PL3976189T3 (pl) | 2024-09-09 |
| US12391679B2 (en) | 2025-08-19 |
| JP7550174B2 (ja) | 2024-09-12 |
| US20220340548A1 (en) | 2022-10-27 |
| CR20210586A (es) | 2022-01-24 |
| ES2985528T3 (es) | 2024-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202193281A1 (ru) | Новые соединения и их фармацевтические композиции для лечения заболеваний | |
| PH12020552160A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| PH12020550725A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| MX2020003863A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. | |
| EA201270076A1 (ru) | Новое соединение, применимое для лечения дегенеративных и воспалительных заболеваний | |
| EA202091512A1 (ru) | Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы | |
| MX2013012281A (es) | Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| EA201892339A3 (ru) | Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания | |
| PH12019502853A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| TW201613601A (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
| PH12021552375A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| EA201992152A1 (ru) | Химические соединения | |
| MX2021014157A (es) | Formas cristalinas de un inhibidor btk. | |
| TW201613873A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| PH12022550843A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| PH12021552377A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| BR112018075415A2 (pt) | composição mastigável macia compreendendo plantago | |
| PH12022550846A1 (en) | Thienopyrimidones as trpa1 inhibitors | |
| PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease | |
| MX2021011575A (es) | Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. | |
| PH12019501853A1 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2022004806A (es) | Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763). | |
| NZ803938A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders. | |
| AR131628A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades |